Cargando…

Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming

The Warburg effect is a unique metabolic feature of the majority of tumor cells and is closely related to chemotherapeutic resistance. Pyruvate dehydrogenase kinase 1 (PDK1) is considered a 'switch' that controls the fate of pyruvate in glucose metabolism. However, to date, to the best of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huadan, He, Yichun, Ma, Jiaoyan, Zhao, Yuanxin, Liu, Yanan, Sun, Liankun, Su, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384842/
https://www.ncbi.nlm.nih.gov/pubmed/32705170
http://dx.doi.org/10.3892/ijo.2020.5098
_version_ 1783563668988887040
author Xu, Huadan
He, Yichun
Ma, Jiaoyan
Zhao, Yuanxin
Liu, Yanan
Sun, Liankun
Su, Jing
author_facet Xu, Huadan
He, Yichun
Ma, Jiaoyan
Zhao, Yuanxin
Liu, Yanan
Sun, Liankun
Su, Jing
author_sort Xu, Huadan
collection PubMed
description The Warburg effect is a unique metabolic feature of the majority of tumor cells and is closely related to chemotherapeutic resistance. Pyruvate dehydrogenase kinase 1 (PDK1) is considered a 'switch' that controls the fate of pyruvate in glucose metabolism. However, to date, to the best of our knowledge, there are only a few studies to available which had studied the reduction of chemotherapeutic resistance via the metabolic reprogramming of tumor cells with PDK1 as a target. In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA). Furthermore, the present study elucidated that the targeting of PDK1 may be a potential strategy for targeting metabolism in the chemotherapy of HCC. In addition, DIC as an 'old drug' exhibits novel efficacy, bringing new hope for antitumor therapy.
format Online
Article
Text
id pubmed-7384842
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-73848422020-07-30 Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming Xu, Huadan He, Yichun Ma, Jiaoyan Zhao, Yuanxin Liu, Yanan Sun, Liankun Su, Jing Int J Oncol Articles The Warburg effect is a unique metabolic feature of the majority of tumor cells and is closely related to chemotherapeutic resistance. Pyruvate dehydrogenase kinase 1 (PDK1) is considered a 'switch' that controls the fate of pyruvate in glucose metabolism. However, to date, to the best of our knowledge, there are only a few studies to available which had studied the reduction of chemotherapeutic resistance via the metabolic reprogramming of tumor cells with PDK1 as a target. In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA). Furthermore, the present study elucidated that the targeting of PDK1 may be a potential strategy for targeting metabolism in the chemotherapy of HCC. In addition, DIC as an 'old drug' exhibits novel efficacy, bringing new hope for antitumor therapy. D.A. Spandidos 2020-07-10 /pmc/articles/PMC7384842/ /pubmed/32705170 http://dx.doi.org/10.3892/ijo.2020.5098 Text en Copyright: © Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Xu, Huadan
He, Yichun
Ma, Jiaoyan
Zhao, Yuanxin
Liu, Yanan
Sun, Liankun
Su, Jing
Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title_full Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title_fullStr Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title_full_unstemmed Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title_short Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
title_sort inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384842/
https://www.ncbi.nlm.nih.gov/pubmed/32705170
http://dx.doi.org/10.3892/ijo.2020.5098
work_keys_str_mv AT xuhuadan inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT heyichun inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT majiaoyan inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT zhaoyuanxin inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT liuyanan inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT sunliankun inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming
AT sujing inhibitionofpyruvatedehydrogenasekinase1bydicoumarolenhancesthesensitivityofhepatocellularcarcinomacellstooxaliplatinviametabolicreprogramming